Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027

Zura Bio Ltd

Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
Net loss improved to $45.4M ($0.60 per share) from $69.2M ($2.09 per share) in 2023.
Initiated Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis (SSc) in Dec 2024; Phase 2 HS trial planned for Q2 2025.
Completed $112.5M private placement in April 2024; also executed warrant exchange and established ATM program in 2024.
Robert Lisicki appointed CEO in April 2024; Kiran Nistala joined as CMO in Jan 2024; Scientific Advisory Board established June 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.